Individual Investigator Research Awards for Clinical Trials (IIRACT) is a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) that funds clinical trials research aimed at preventing and curing cancer in Texas. The program supports Texas-based entities conducting clinical trials across cancer types, with applications accepted through May 20, 2026 (RRCTA mechanism) and with an April 28, 2026 deadline for individual investigator awards. Eligible applicants include nonprofit institutions and private companies based in Texas. CPRIT now supports ORCID IDs in applicant profiles to streamline the application process.

CPRIT Seed Company Award (RFA C-26.1-SEED) is a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) that funds early-stage Texas-based companies developing cancer prevention or research products. The Seed Award supports product development research — including therapeutics, diagnostics, and new technologies — for companies at the pre-commercialization stage looking to advance their cancer-related innovations toward market readiness. CPRIT's product development grants are designed to catalyze commercial investment and keep cancer-focused companies growing within Texas. Eligible applicants are Texas-based for-profit companies, or companies willing to relocate to Texas. Awards are available up to ,000,000. The deadline for preliminary applications is April 16, 2026, with full applications due June 10, 2026.

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA) is sponsored by Cancer Prevention and Research Institute of Texas (CPRIT). Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near- or long-term.

NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.